Last reviewed · How we verify
met or diet
met or diet is a Small molecule drug developed by Huazhong University of Science and Technology. It is currently in Phase 1 development. Also known as: metformin, diet control.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | met or diet |
|---|---|
| Also known as | metformin, diet control |
| Sponsor | Huazhong University of Science and Technology |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Sinusitis
- Depressive symptoms
- Back pain
- Gestational diabetes
- Common cold
- Cough
- Oral candidiasis
- Arthralgia
- Headache
- Chest pains
- COVID-19
- Diarrhoea
Key clinical trials
- STRONGER 60+: Assessing the Clinical Effectiveness and Delivery of an Adapted FINGER Model for Brain Health in Primary Care (NA)
- Dyad Plus Effectiveness/Feasibility (NA)
- Telemedicine-Based Integrated Care for Heart Failure Prevention in Older Patients With Atrial Fibrillation (MIRACLE-AF III) (NA)
- Nutrition and Pain Study (NA)
- Postprandial Nutrient Homeostasis Before and After Weight Loss Induced by Low-calorie Diet or RYGB (NA)
- Standardized Nutritional Management of Pediatric Patients With Solid Tumors (NA)
- Physical Activity and Nutrition to Halt Elevated Risk in the Pancreas Interception Center (NA)
- Prehab for Adult Spinal Deformity Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- met or diet CI brief — competitive landscape report
- met or diet updates RSS · CI watch RSS
- Huazhong University of Science and Technology portfolio CI
Frequently asked questions about met or diet
What is met or diet?
Who makes met or diet?
Is met or diet also known as anything else?
What development phase is met or diet in?
What are the side effects of met or diet?
Related
- Manufacturer: Huazhong University of Science and Technology — full pipeline
- Also known as: metformin, diet control
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing